AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29219131 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Childhood Education (ECE) activity
Number of subjects: 210
Study 29219131 — intervention group
Group type: EXPERIMENTAL
Intervention: School readiness assessment
Number of subjects: 210
Study 29219131 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical facilities and classroom performance
Number of subjects: 210
Study 29219131 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive supervision and home environment
Number of subjects: 210
Study 25840082 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubeless mini-percutaneous nephrolithotomy (MPCNL)
Number of subjects: 78
Study 25840082 — intervention group
Group type: COMPARATOR
Intervention: Standard percutaneous nephrolithotomy (PCNL)
Number of subjects: 78
Study 23061422 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 141
Study 23061422 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial vaginosis (BV) among female source partners
Number of subjects: 141
Study 23061422 — intervention group
Group type: EXPERIMENTAL
Intervention: Male circumcision
Number of subjects: 141
Study 23061422 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma HIV‐1 in source partners
Number of subjects: 141
Study 21978944 — intervention group
Group type: EXPERIMENTAL
Intervention: E2/DRSP (17β‐estradiol 1mg plus drospirenone 2mg)
Number of subjects: 80
Study 21978944 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 19775043 — intervention group
Group type: EXPERIMENTAL
Intervention: Customised APACHE II
Number of subjects: 2040
Study 19775043 — intervention group
Group type: EXPERIMENTAL
Intervention: Customised SAPS II
Number of subjects: 2040
Study 16546481 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (HP; 3.6 g/kg)
Number of subjects: 5
Study 16546481 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-protein diet (MP; 1.8 g/kg)
Number of subjects: 5
Study 16546481 — intervention group
Group type: COMPARATOR
Intervention: Low-protein diet (LP; 0.8 g/kg)
Number of subjects: 5
Study 12769147 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid gas-permeable lens (tisilfocon A)
Number of subjects: 0
Study 12769147 — intervention group
Group type: COMPARATOR
Intervention: Hydrogel lens (etafilcon A)
Number of subjects: 0
Study 11086437 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: ADR, EPI, CDDP or 5‐FU alone (initially)
Number of subjects: 49
Study 11086437 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: CDDP 50 mg on day 1, 5‐FU 500 mg/day from day 2 to day 7 and 5‐FU 500 mg/day for 2 weeks thereafter (FP treatment)
Number of subjects: 49
Study 11086437 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: CDDP 50 mg at reservoir insertion and 5‐FU 1,000 mg for 5 hours thereafter (WHF treatment)
Number of subjects: 49
Study 11086437 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D: 5‐FU 1,000 mg for 24 hours on day 1, day 3, and day 5 of every week with CDDP 5‐10 mg/day from day 1 to day 5 (intermittent F + low‐dose P treatment) for 3 weeks
Number of subjects: 49
Study 9323551 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate injection (300 mg)
Number of subjects: 12
Study 8405006 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 3
Study 8405006 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 7.5 mg
Number of subjects: 3
Study 8405006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 3899352 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergolide
Number of subjects: 17
Study 30359476 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (adjusted to achieve a serum level > 30 ng/mL) with calcium (1,200 mg)
Number of subjects: 260
Study 30359476 — intervention group
Group type: COMPARATOR
Intervention: Placebo with calcium (1,200 mg)
Number of subjects: 260
Study 30589035 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic duct ligation
Number of subjects: 60
Study 30589035 — intervention group
Group type: COMPARATOR
Intervention: Nonligation
Number of subjects: 60
Study 27389564 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 654
Study 24702522 — intervention group
Group type: EXPERIMENTAL
Intervention: SWIFT-Acute
Number of subjects: 64
Study 24702522 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 64
Study 24702522 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64
Study 22197003 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg of hydrocortisone
Number of subjects: 44
Study 22197003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 19713952 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat (HF) meal
Number of subjects: 10
Study 19713952 — intervention group
Group type: COMPARATOR
Intervention: Moderate-fat (MF) meal
Number of subjects: 10
Study 18034852 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual toothbrush
Number of subjects: 93
Study 18034852 — intervention group
Group type: COMPARATOR
Intervention: Toothbrush + floss
Number of subjects: 93
Study 15869318 — intervention group
Group type: EXPERIMENTAL
Intervention: rAHF-PFM
Number of subjects: 0
Study 11640942 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiobsessive drug treatment
Number of subjects: 34
Study 11640942 — intervention group
Group type: COMPARATOR
Intervention: OCD patients
Number of subjects: 34
Study 11640942 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 34
Study 11640942 — intervention group
Group type: COMPARATOR
Intervention: Patients with panic disorder
Number of subjects: 34
Study 9846013 — intervention group
Group type: EXPERIMENTAL
Intervention: T‐PLL cases
Number of subjects: 10
Study 9846013 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytogenetic analysis
Number of subjects: 10
Study 8608331 — intervention group
Group type: EXPERIMENTAL
Intervention: Train-the-trainer and consultation approach for 22 clinics
Number of subjects: 44
Study 8608331 — intervention group
Group type: COMPARATOR
Intervention: Control group of 22 clinics left alone
Number of subjects: 44
Study 2511700 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentalong longo (40 mg PETN)
Number of subjects: 0
Study 2511700 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentalong (20 mg)
Number of subjects: 0
Study 2511700 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentalong longo (40 mg PETN) with five layers of coating
Number of subjects: 0
Study 1071702 — intervention group
Group type: EXPERIMENTAL
Intervention: Special hypertension programme
Number of subjects: 100
Study 1071702 — intervention group
Group type: COMPARATOR
Intervention: Reference practices
Number of subjects: 100
Study 30868790 — intervention group
Group type: EXPERIMENTAL
Intervention: LHW uncovered areas
Number of subjects: 102
Study 30868790 — intervention group
Group type: COMPARATOR
Intervention: LHW covered areas
Number of subjects: 102
Study 29141164 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomustine plus Bevacizumab (combination group)
Number of subjects: 437
Study 29141164 — intervention group
Group type: COMPARATOR
Intervention: Lomustine alone (monotherapy group)
Number of subjects: 437
Study 25956152 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexually arousing visual stimuli (movie trailers, music video clips, and TV commercials)
Number of subjects: 64
Study 25956152 — intervention group
Group type: COMPARATOR
Intervention: Nature documentary without sexual content (control group)
Number of subjects: 64
Study 23992877 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus erlotinib (p.o. 150 mg/day)
Number of subjects: 124
Study 23992877 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab plus chemotherapy (gemcitabine/cisplatin or carboplatin/paclitaxel standard doses)
Number of subjects: 124
Study 21236473 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted radical hysterectomy (RRH)
Number of subjects: 1256
Study 21236473 — intervention group
Group type: COMPARATOR
Intervention: Total laparoscopic radical hysterectomy (TLRH)
Number of subjects: 1256
Study 19425822 — intervention group
Group type: EXPERIMENTAL
Intervention: Inosine
Number of subjects: 16
Study 17021714 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole 400 mg/day
Number of subjects: 40
Study 17021714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15104559 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH replacement therapy for 4 years
Number of subjects: 30
Study 15104559 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH replacement therapy + alendronate (10 mg/day) for 3 years
Number of subjects: 30
Study 15104559 — intervention group
Group type: COMPARATOR
Intervention: Control group continuing on rhGH replacement alone
Number of subjects: 30
Study 15104559 — intervention group
Group type: EXPERIMENTAL
Intervention: alendronate treatment
Number of subjects: 30
Study 10646710 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual endoscopy (VE)
Number of subjects: 30
Study 10646710 — intervention group
Group type: COMPARATOR
Intervention: Actual endoscopy
Number of subjects: 30
Study 9764990 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin (400 mg/day for 6 months)
Number of subjects: 107
Study 9764990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 7836511 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 486 (200 mg)
Number of subjects: 0
Study 7836511 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (500 mg every 12 hours for five doses starting 4 days after LH surge)
Number of subjects: 0
Study 7836511 — intervention group
Group type: COMPARATOR
Intervention: Control cycle (no treatment)
Number of subjects: 0
Study 2899719 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant alpha 2‐interferon at doses of 2.5, 5, or 10 X 10(6) U/m2 intramuscularly thrice weekly for 12‐24 weeks
Number of subjects: 72
Study 2899719 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant alpha 2‐interferon
Number of subjects: 72
Study 2899719 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 72
Study 31784746 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating triglycerides (TG) measured via log transformation of mg/dl data
Number of subjects: 16000
Study 31784746 — intervention group
Group type: COMPARATOR
Intervention: Genetic determinants of HbA1c
Number of subjects: 16000
Study 29530067 — intervention group
Group type: EXPERIMENTAL
Intervention: Chance UK's mentoring programme
Number of subjects: 246
Study 29530067 — intervention group
Group type: COMPARATOR
Intervention: Services as usual
Number of subjects: 246
Study 26901007 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g I/kg BW
Number of subjects: 111
Study 26901007 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 g I/kg BW
Number of subjects: 111
Study 26901007 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 g I/kg BW
Number of subjects: 111
Study 26901007 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 111
Study 25105787 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive plate osteosynthesis (MIPO) with locking compression plate (LCP)
Number of subjects: 49
Study 25105787 — intervention group
Group type: COMPARATOR
Intervention: Intramedullary nailing (EHN)
Number of subjects: 49
Study 22560729 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) intervention
Number of subjects: 177
Study 19023658 — intervention group
Group type: EXPERIMENTAL
Intervention: Levo‐alpha‐acetylmethadol maintenance (LAAM)
Number of subjects: 315
Study 19023658 — intervention group
Group type: COMPARATOR
Intervention: Methadone maintenance (MM)
Number of subjects: 315
Study 19023658 — intervention group
Group type: EXPERIMENTAL
Intervention: LAAM
Number of subjects: 315
Study 17161535 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine 400 mg
Number of subjects: 360
Study 17161535 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine 300 mg
Number of subjects: 360
Study 17161535 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine 200 mg
Number of subjects: 360
Study 17161535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 17161535 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (pooled data)
Number of subjects: 360
Study 17161535 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (300 and 400 mg)
Number of subjects: 360
Study 17161535 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 360
Study 15815089 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural network classifier using multispectral imaging system
Number of subjects: 1278
Study 15815089 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural network classifier using multispectral imaging system with additional set of 1022 lesions
Number of subjects: 1278
Study 12297167 — intervention group
Group type: EXPERIMENTAL
Intervention: MECC system
Number of subjects: 60
Study 12297167 — intervention group
Group type: COMPARATOR
Intervention: Standard CPB
Number of subjects: 60
Study 10445538 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral magnesium citrate (296 cc) with oral bisacodyl (10 mg)
Number of subjects: 291
Study 10445538 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral magnesium citrate (296 cc) with one hypertonic phosphate enema
Number of subjects: 291
Study 10445538 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral magnesium citrate (296 cc) with two hypertonic phosphate enemas
Number of subjects: 291
Study 10445538 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bisacodyl regimen
Number of subjects: 291
Study 10445538 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bisacodyl preparation
Number of subjects: 291
Study 7847429 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone injections (0.05 mg/kg IBW for 28 days)
Number of subjects: 11
Study 2111981 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% albumin supplementation
Number of subjects: 40
Study 2111981 — intervention group
Group type: COMPARATOR
Intervention: No concentrated albumin (control)
Number of subjects: 40
Study 387417 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirbuterol 10 mg plus hydroxyzine 10 mg
Number of subjects: 17
Study 387417 — intervention group
Group type: COMPARATOR
Intervention: Pirbuterol 10 mg plus placebo
Number of subjects: 17
Study 6123281 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg
Number of subjects: 145
Study 6123281 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 145
Study 6123281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 31309815 — intervention group
Group type: EXPERIMENTAL
Intervention: Dumbbell weight 0.48 kg, shoulder flexion 150°/elbow 180°
Number of subjects: 15
Study 31309815 — intervention group
Group type: EXPERIMENTAL
Intervention: Dumbbell weight 0.48 kg, shoulder flexion 120°/elbow 150°
Number of subjects: 15
Study 31309815 — intervention group
Group type: EXPERIMENTAL
Intervention: Dumbbell weight 0.48 kg, shoulder flexion 90°/elbow 120°
Number of subjects: 15
Study 31309815 — intervention group
Group type: EXPERIMENTAL
Intervention: Dumbbell weight 0.48 kg, shoulder flexion 60°/elbow 90°
Number of subjects: 15
Study 31309815 — intervention group
Group type: EXPERIMENTAL
Intervention: Dumbbell weight 0.75 kg, shoulder flexion 150°/elbow 180°
Number of subjects: 15
Study 31309815 — intervention group
Group type: EXPERIMENTAL
Intervention: Dumbbell weight 0.75 kg, shoulder flexion 120°/elbow 150°
Number of subjects: 15
Study 31309815 — intervention group
Group type: EXPERIMENTAL
Intervention: Dumbbell weight 0.75 kg, shoulder flexion 90°/elbow 120°
Number of subjects: 15
Study 31309815 — intervention group
Group type: EXPERIMENTAL
Intervention: Dumbbell weight 0.75 kg, shoulder flexion 60°/elbow 90°
Number of subjects: 15
Study 28655715 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabilone
Number of subjects: 60
Study 28655715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28655715 — intervention group
Group type: EXPERIMENTAL
Intervention: BLSA Obese Group
Number of subjects: 60
Study 28655715 — intervention group
Group type: COMPARATOR
Intervention: BLSA Lean Group
Number of subjects: 60
Study 24590990 — intervention group
Group type: EXPERIMENTAL
Intervention: Drainage
Number of subjects: 168
Study 24590990 — intervention group
Group type: COMPARATOR
Intervention: Non-drainage
Number of subjects: 168
Study 23092595 — intervention group
Group type: EXPERIMENTAL
Intervention: DVD-based training program for informal caregivers
Number of subjects: 29
Study 23092595 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 29
Study 17878794 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft lullaby music
Number of subjects: 69
Study 17878794 — intervention group
Group type: COMPARATOR
Intervention: No music
Number of subjects: 69
Study 14693576 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg/kg FDP IV before surgery and 2.5 mM FDP as a cardioplegic additive (n = 15)
Number of subjects: 120
Study 14693576 — intervention group
Group type: EXPERIMENTAL
Intervention: FDP treatment across all regimens (n = 88; 44 FDP, 44 control)
Number of subjects: 120
Study 11836046 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate 625 mg (250 mg elemental calcium) three times a day (group A)
Number of subjects: 56
Study 11836046 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate 625 mg (250 mg elemental calcium) plus 0.625 mg/day of conjugated equine estrogen and 5 mg medrogestone acetate (group B)
Number of subjects: 56
Study 10071455 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor (G-CSF)
Number of subjects: 214
Study 10071455 — intervention group
Group type: COMPARATOR
Intervention: Control (flomoxef sodium and tobramycin without G-CSF)
Number of subjects: 214
Study 8530843 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm group (Calafiore technique)
Number of subjects: 20
Study 8530843 — intervention group
Group type: COMPARATOR
Intervention: Cold group (traditional technique)
Number of subjects: 20
Study 2247106 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐64077 (5‐lipoxygenase inhibitor)
Number of subjects: 13
Study 7443930 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontalis EMG biofeedback
Number of subjects: 24
Study 7443930 — intervention group
Group type: COMPARATOR
Intervention: No-feedback (instructions only)
Number of subjects: 24
Study 7443930 — intervention group
Group type: COMPARATOR
Intervention: Adaptation control condition
Number of subjects: 24
Study 30578758 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow-derived mesenchymal stem cell transplantation (MSCT)
Number of subjects: 28
Study 30578758 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic cultivated limbal epithelial transplantation (CLET)
Number of subjects: 28
Study 24464327 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega‐3/6 fatty acids (Equazen eye q™)
Number of subjects: 90
Study 24464327 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 90
Study 24464327 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined MPH + Omega‐3/6
Number of subjects: 90
Study 24464327 — intervention group
Group type: COMPARATOR
Intervention: Omega‐3/6
Number of subjects: 90
Study 24464327 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate (MPH) alone
Number of subjects: 90
Study 25770987 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-bonded grafts
Number of subjects: 160
Study 25770987 — intervention group
Group type: COMPARATOR
Intervention: Standard grafts
Number of subjects: 160
Study 23406190 — intervention group
Group type: EXPERIMENTAL
Intervention: RYGB (Laparoscopic Roux-en-Y Gastric Bypass)
Number of subjects: 139
Study 23406190 — intervention group
Group type: COMPARATOR
Intervention: ILI (Intensive Lifestyle Intervention)
Number of subjects: 139
Study 20680272 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial head replacement
Number of subjects: 45
Study 20680272 — intervention group
Group type: COMPARATOR
Intervention: Open reduction and internal fixation (ORIF)
Number of subjects: 45
Study 19156437 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid intake to maintain body mass (BM)
Number of subjects: 8
Study 19156437 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid intake to increase BM by 2%
Number of subjects: 8
Study 19156437 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid intake to decrease BM by 2%
Number of subjects: 8
Study 19156437 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid intake to decrease BM by 4%
Number of subjects: 8
Study 19156437 — intervention group
Group type: COMPARATOR
Intervention: No fluid intake
Number of subjects: 8
Study 17047639 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertriglyceridemic waist (HTGW) defined as waist circumference (WC) > or =90 cm and triglycerides (TG) > or =2 mmol/l
Number of subjects: 3430
Study 17047639 — intervention group
Group type: COMPARATOR
Intervention: Low WC/low TG
Number of subjects: 3430
Study 17047639 — intervention group
Group type: COMPARATOR
Intervention: High WC/low TG
Number of subjects: 3430
Study 17047639 — intervention group
Group type: COMPARATOR
Intervention: Low WC/high TG
Number of subjects: 3430
Study 17047639 — intervention group
Group type: EXPERIMENTAL
Intervention: HTGW
Number of subjects: 3430
Study 14765138 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral repetitive magnetic stimulation
Number of subjects: 31
Study 14765138 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 31
Study 12269876 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A)
Number of subjects: 19
Study 12269876 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 19
Study 12269876 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 19
Study 10763657 — intervention group
Group type: EXPERIMENTAL
Intervention: Home care instruction
Number of subjects: 0
Study 7779548 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (100 micrograms daily as enriched yeast for 4 months)
Number of subjects: 19
Study 7779548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 7779548 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation
Number of subjects: 19